Cargando…

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review

SIMPLE SUMMARY: HER2-positive breast cancer (BC) is associated with an aggressive clinicopathological nature and is known to have a poor prognosis. Their tumor proliferation features can lead to visceral metastasis disseminating to the brain, liver, lung, and bone. Delivering standard chemotherapy H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giffoni de Mello Morais Mata, Danilo, Chehade, Rania, Hannouf, Malek B., Raphael, Jacques, Blanchette, Phillip, Al-Humiqani, Abdullah, Ray, Monali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486709/ https://www.ncbi.nlm.nih.gov/pubmed/37686612 http://dx.doi.org/10.3390/cancers15174336

Ejemplares similares

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
por: Mata, Danilo Giffoni de Mello Morais, et al.
Publicado: (2022)

Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review
por: Xiao, Tian, et al.
Publicado: (2023)

Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008–2012
por: Hannouf, Malek, et al.
Publicado: (2021)

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
por: Stewart, Paul, et al.
Publicado: (2020)

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
por: Hannouf, Malek B, et al.
Publicado: (2012)

HER2-LOW BREAST CANCER BRAIN METASTASES: INCIDENCE AND TREATMENT IMPLICATIONS
por: Chehade, Rania, et al.
Publicado: (2023)

A Population-Based Study to Evaluate the Associations of Nodal Stage, Lymph Node Ratio and Log Odds of Positive Lymph Nodes with Survival in Patients with Small Bowel Adenocarcinoma
por: Batra, Atul, et al.
Publicado: (2022)

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer
por: Fernandes, Ricardo, et al.
Publicado: (2023)

Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
por: Batra, Atul, et al.
Publicado: (2020)

Infracentimetric HER-2 positive breast tumours—review of the literature
por: da Fonseca Reis Silva, Danilo, et al.
Publicado: (2015)

The Self-Appraisal of Masking Instrument
por: Block, Ray, et al.
Publicado: (2022)

Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers
por: Marchini, Cristina, et al.
Publicado: (2013)

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
por: Pous, Anna, et al.
Publicado: (2023)

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2023)

How to appraise the effectiveness of treatment
por: Stewart, Suzanne B., et al.
Publicado: (2011)

Quality and impact of appraisal for revalidation: the perceptions of London’s responsible officers and their appraisers
por: Griffin, Ann, et al.
Publicado: (2015)

Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer
por: Hannouf, Malek B., et al.
Publicado: (2012)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
por: Wong, Andrea L. A., et al.
Publicado: (2012)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies
por: Hrynchak, Ivanna, et al.
Publicado: (2021)

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2021)

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
por: Wu, Xiaofan, et al.
Publicado: (2022)

Rescue strategies for refractory hypoxemia: a critical appraisal
por: Villar, Jesús, et al.
Publicado: (2009)

Adaptation to stress in football athletes: The importance of cognitive appraisal
por: Gomes, A. Rui, et al.
Publicado: (2022)

Results of the Willingness To Pay Study for FCC in Switzerland.
por: Giffoni, Francesco
Publicado: (2020)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
por: Krawczyk, Natalia, et al.
Publicado: (2022)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Orozco Leal, Giovany, et al.
Publicado: (2023)

Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature
por: Bech, Rikke, et al.
Publicado: (2018)

Male reproductive health challenges: appraisal of wives coping strategies
por: Amoo, Emmanuel O., et al.
Publicado: (2017)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
por: Casanova, M, et al.
Publicado: (2011)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Perforated gastric cancer: a critical appraisal
por: Di Carlo, Sara, et al.
Publicado: (2021)

Appraisal
por: Peters, Andreas Joachim
Publicado: (2020)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c6ngt7ee6gbkt6gn034urorrcb